The objective of this study was to determine the @entity560 status and its relationship with disease and therapy features and with bone mineral density in @entity1 with @entity1252 . Non-pregnant @entity1252 @entity1 with dual-energy X-ray absorptiometry and @entity560 measurements performed between @entity4456 2005 and August 31 2006 were studied. In each @entity1 , the lowest T-score of the first dual-energy X-ray absorptiometry scan during the study period was used. In postmenopausal @entity1 , a T-score > or = 1.0 standard deviation was considered normal, between -1.0 and -2.5 standard deviations @entity2331 and < or = 2.5 standard deviations @entity170 ; in premenopausal @entity1 a T-score > or = 2.5 standard deviations was normal and < or = 2.5 standard deviations defined as reduced bone density. @entity14257 and @entity10692 levels were determined at the time of dual-energy X-ray absorptiometry. A @entity14257 level of <80 nmol/L was defined as sub-optimal and a level <40 nmol/L as deficient. Demographic and clinical variables were investigated for association with @entity560 levels by univariate and multivariate analyses. One-hundred and twenty-four @entity1252 @entity1 had dual-energy X-ray absorptiometry scans and @entity560 assays performed during the study period. Sub-optimal @entity14257 levels were found in 82 (66.7%) and deficient @entity14257 levels in 22 (17.9%) @entity1 . The disease-related features examined at the time of @entity560 assays or bone mineral density showed no correlation with @entity560 levels by univariate analyses. Neither @entity14257 nor @entity10692 was associated with bone mineral density status among these @entity1 . A multivariate logistic regression model identified season, cumulative glucocorticoid exposure, and serum @entity1011 as being associated with @entity14257 levels, whereas ethnicity, glucocorticoid exposure, and serum @entity1011 were associated with @entity10692 levels. In conclusion, sub-optimal @entity560 status is common in @entity1 with @entity1252 and is related to season, cumulative glucocorticoid dose, and serum @entity1011 .

XXXX insufficiency in a large female SLE cohort.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity10692 :: ('MESH:C097949', 'Chemical') :: ['1,25-dihydroxyvitamin D'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity4456 :: ('5580', 'Gene') :: ['May 1'] @entity14257 :: ('MESH:C104450', 'Chemical') :: ['25-hydroxyvitamin D'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity560 :: (MESH:D014807,Chemical) :: ['Vitamin D']
